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Abstract
Background: The recently observed association between the APOC3-related rs10892151 polymorphism and serum
triglyceride levels has prompted us the possibility to explore whether this genetic variant may play a major role in
human immunodeficiency virus (HIV)/antiretroviral therapy-induced dyslipidemia.
Methods: We determined the rs10892151 genotype distribution and serum apolipoprotein (apo) C-III
concentration in a group of HIV-infected patients (n = 208) and in a group of age and sex-matched healthy
volunteers (n = 200). Circulating lipid and lipoprotein levels were followed for 12 months after antiretroviral
treatment initiation in the HIV-infected group.
Results: There were no significant variations in the frequency of the A allele between the healthy and HIV-infected
groups (7.5 vs. 8.6%, respectively; p = 0.7); additionally, the A allele was not related to serum apo C-III
concentration. However, among patients receiving protease inhibitor (PI) treatment, carriers of the A allele had
significantly increased serum triglyceride (5.76 ± 2.54 mmol/L) and total cholesterol (6.63 ± 2.85 mmol/L)
concentrations together with depressed levels of HDL-cholesterol (0.75 ± 0.3 mmol/L) when compared with
patients not carrying the allele (2.43 ± 1.32, 5.2 ± 2.17 and 1.24 ± 0.4 mmol/L, respectively) at the end of the study.
This effect was only evident for HDL-cholesterol concentration when patients were treated with non-nucleoside
reverse transcriptase inhibitors (1.05 ± 0.4 vs. 1.28 ± 0.4 mmol/L).
Conclusions: The A allelic variant of the rs10892151 polymorphism is not associated with serum apo C-III
concentration, but predisposes HIV-infected patients to less favorable lipid profile, particularly in those patients
treated with PIs.
Background
The introduction of antiretroviral therapies has led to a
remarkable increase in the life expectancy of patients
with human immunodeficiency virus (HIV) infection.
Unfortunately, current treatment may cause a wide
spectrum of metabolic disturbances and comorbid con-
ditions, with cardiovascular disease as an important
example [1]. Dyslipidemia is particularly frequent and is
mostly characterized by hypertriglyceridemia and low
HDL-cholesterol concentrations. Although this
phenomenon has been attributed, at least in part, to the
use of protease inhibitors (i.e., ritonavir or ritonavir-
boosted treatment), dyslipidemia is also observed in
treatment-naïve HIV-infected patients, suggesting that
HIV infection itself has a metabolically deleterious effect
[2,3].
Susceptibility to developing these metabolic derange-
ments, specifically hypertriglyceridemia, varies among
individuals and could be influenced by genetic variability
[4]. In an attempt to find new candidate genes responsi-
ble for variations in lipid concentrations, we have
explored the rs10892151 polymorphism, which is
located within an intron of the DSCAML1 (Down syn-
drome cell adhesion molecule like-1) gene and is in
* Correspondence: jorge.joven@urv.cat
1Centre de Recerca Biomèdica, Universitat Rovira i Virgili, Institut
d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
Full list of author information is available at the end of the article
Aragonès et al. BMC Medical Genetics 2011, 12:120
http://www.biomedcentral.com/1471-2350/12/120
© 2011 Aragonès et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.linkage disequilibrium with a loss-of-function mutation
in the APOC3 gene. Carriers of this null mutation have
low circulating apolipoprotein (apo) C-III levels and
reduced fasting and post-prandial triglyceride concentra-
tions [5], which is likely due to the well-established
function of apo C-III as an inhibitor of lipoprotein lipase
[6]. Other functions attributed to apo C-III include a
reduction in the hepatic uptake of apo B-containing
lipoproteins [7,8] as well as an increase in the catabo-
lism of high-density lipoprotein (HDL) particles [9],
adhesion of monocytes to vascular endothelial cells [10],
and the activation of inflammatory signaling pathways
[11].
Because HIV-associated dyslipidemia is accompanied
by increases in apoB-containing lipoproteins, impaired
lipolysis, and decreases in HDL-cholesterol levels [12],
we hypothesized that in HIV-infected patients, the
rs10892151 polymorphism could be an important
genetic factor influencing the deleterious effect of HIV
on lipid profile. Hence, we investigated treatment-
induced lipid and lipoprotein changes in HIV-infected
patients who were segregated with respect to their treat-
ment strategy and their rs10892151 genotype.
Methods
Subjects and study design
We recruited patients from among the participants of a
longitudinal project assessing atherosclerosis in HIV-
infected patients [13,14] from January 2001 through
December 2004; all subjects agreed to participate in the
present study and provided informed consent. The
initial time-point of this study was the commencement
of therapy with protease inhibitors (PIs) or with non-
nucleoside reverse transcriptase inhibitors (NNRTIs)
based schemes. The antiretroviral adjuvant drugs were
zidovudine, lamivudine or stavudine. Follow-up was
conducted at 3, 6, and 12 months after treatment initia-
tion. Candidates for inclusion were naïve patients, and
patients previously exposed to antiretroviral treatment
who had discontinued treatment for at least 6 months.
No patient was being treated with lipid-lowering drugs
at the commencement of the study, but 20 patients
were treated with fluvastatin (80 mg/day) during the fol-
low-up. For the purpose of this study, only patients who
remained on the same antiretroviral treatment regimen
during follow-up were included in the analysis. For the
control group, we selected 200 age and sex-matched
healthy volunteers who participated in an epidemiologi-
cal study, the details of which have been previously
reported [15]. The study was approved by the Ethics
Committee of the Hospital Universitari de Sant Joan de
Reus.
Clinical and Laboratory Measurements
Detailed clinical characteristics of each subject were
recorded, and a thorough physical examination was per-
formed during the interview. We recorded data regard-
ing HIV infection, including opportunistic infections,
mode of HIV transmission, CD4+ T cell count, HIV
viral load, presence of lipodystrophy and HCV co-infec-
tion status. Body mass index (BMI) was defined as
weight (kg)/height
2 (m
2). Fasting serum glucose, choles-
terol, triglycerides, highly sensitive C-reactive protein
(CRP) and apo C-III concentrations were measured with
the LXi 725-Synchron (Beckman Coulter, Fullerton,
California, USA) automatic analyzer using enzymatic
assays or chemiluminescent immunoassays. HDL- and
LDL-cholesterol levels were measured as described
[16,17]. Serum concentration of monocyte chemoattrac-
tant protein-1 (MCP-1) was measured with an enzyme-
linked immunosorbent assay (Human MCP-1 ELISA,
PeproTech, London, UK).
Genotyping
Participants were genotyped for the rs10892151 poly-
morphism using the TaqMan 5’ allelic discrimination
assay by the custom TaqMan SNP Genotyping Assay
C_3239453_10 (Applied Biosystems, Foster City, CA)
[18]. Amplifications were performed in a 7900HT
Sequencing Detection System (Applied Biosystems) for
continuous fluorescence monitoring.
Statistical analyses
Analysis was performed using SPSS, version 18.0 (SPSS
Inc., Chicago, IL). All data are presented as mean ± SD,
except where otherwise stated. The Kolmogorov-Smir-
nov test was used to check whether data were normally
distributed. The Hardy-Weinberg equilibrium (HWE)
for the SNP was tested with the c
2 test. Allele and geno-
type frequencies between cases and controls were com-
pared with the c
2 analysis. Differences in baseline
characteristics between the two treatment groups were
assessed through the c
2 and Mann-Whitney U test for
categorical and continuous variables, respectively. To
asses whether changes in lipid levels at months 0, 3, 6,
and 12 were significantly different from baseline in each
treatment group, and whether those changes were sig-
nificantly different between the two treatment groups,
we used linear mixed models including the interaction
between treatment group and month of therapy as cate-
gorical. Linear mixed models allowed us to accommo-
date multiple measures per person. Univariate and
multivariate analyses were performed, with adjustment
for confounding factors such as sex, age, BMI, co-infec-
tion with HCV, lipodystrophy and lipid-lowering
therapy.
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Characteristics of participants
Of 208 Caucasian subjects who met selection criteria,
113 (54.3%) initiated NNRTI and 95 (45.7%) PI based
scheme. The second component of the regimen were
two non nucleoside reverse transcriptase inhibitor [zido-
vudine (70.2%), lamivudine (91.3%) or stavudine (38.5%)
in patients treated with NNRTI, and zidovudine (77.8%),
lamivudine (84.8%) or stavudine (37.4%) in patients trea-
ted with PI; p = 0.8]. Of the 208 patients initially
selected, 201, 198 and 192 of them remained on the
same ART regimen at months 3, 6 and 12 of follow-up,
respectively. 160 (76.9%) were treatment-naïve patients
(95 in NNRTI group and 65 in the PI group, p = 0.62),
and 48 (23.1%) were patients reinitiating antiretroviral
therapy after treatment interruption for at least 6
months (18 in NNRTI group and 30 in the PI group, p
= 0.79).
The baseline clinically relevant characteristics of the
patients included in the study are summarized in Table
1. The mean time from diagnosis was 7.24 ± 0.36 years,
and 133 (63.9%) patients were co-infected with hepatitis
C virus. These patients were either current or past intra-
venous drug users (60.1%) or became infected as a result
of sexual intercourse. The baseline examination revealed
that most patients were heavy smokers, were relatively
young, were not significantly obese and had normal
blood pressure values.
rs10892151 genotype distribution
The genotype and allelic frequencies of the rs10892151
polymorphism did not show significant variations
between healthy and HIV-infected participants (p = 0.7).
A total of 18 subjects (8.6%) from the HIV-infected
group and 15 (7.5%) from the healthy group were car-
riers of the A allele, while 190 (91.4%) HIV-infected
patients and 185 (92.5%) healthy subjects were carriers
of two G alleles (the wild-type genotype). No subjects
were homozygous for the A allele. The A allelic fre-
quency for these populations was similar to that
reported in the National Center for Biotechnology Infor-
mation SNP public database; it was not significantly dif-
ferent to that predicted by the Hardy-Weinberg
distribution.
When we examined serum apo C-III concentration
based on genotypes, no statistically significant differ-
ences were observed in serum apo C-III levels among
healthy participants [9.21 (3.7) μg/mL in G/G carriers
versus 8.91 (3.5) μg/mL in A/G carriers; p = 0.8] or
among HIV-infected patients [10.49 (4.8) μg/mL in G/G
carriers versus 10.34 (4.8) μg/mL in A/G carriers; p =
0.7]. We also failed to observe significant associations
between the duration and nature of antiretroviral treat-
ment or viral load and serum apo C-III concentration as
well as between lipid profile and rs10892151 genotype
distribution in healthy participants.
Effects of rs10892151 polymorphism on metabolic
variables
Table 2 depicts the main baseline characteristics of
HIV-infected patients segregated according to
rs10892151 genotype variants and treatment scheme.
No significant differences were observed between groups
for the variables considered here. It was only in the sub-
set of HIV-infected patients without HCV co-infection
that carriers of the A allele displayed a trend towards a
favorable lipid profile when compared to non-carriers;
however, this difference did not reach statistical signifi-
cance (data not shown).
Course of lipid disturbances in patients receiving either PI
or NNRTI therapy
Because hyperlipidemia is strongly associated with the
PI treatment regimen, we focused on a subgroup of 95
patients receiving PIs as a component of their antiretro-
viral therapy, and we analyzed lipid profile changes over
Table 1 Baseline main clinical and demographic
characteristics of HIV-infected patients based on
rs10892151 genotype
Characteristics at study entry G/G carriers
(n = 190)
A/G carriers
(n = 18)
Age, years 39.1 (6.9) 37.9 (7.0)
Gender, n (%)
Male 127 (66.8) 13 (72.2)
Female 63 (33.2) 5 (27.8)
BMI, kg/m
2 22.74 (2.9) 23.23 (3.6)
Risk factors for HIV, n (%)
Intravenous drug use 114 (60.0) 11 (61.1)
Heterosexual contact 57 (30.0) 5 (27.7)
Male homosexual contact 19 (10.0) 2 (11.2)
HCV co-infection, n (%) 115 (60.5) 13 (72.2)
HIV-1 RNA viral load, copies/mL 246582 (776921) 336652 (863524)
CD4+ T cell count, cells/μL 448.9 (285.9) 435.1 (290.9)
Treatment scheme, n (%)
NNRTI based 103 (54.2) 10 (55.5)
PI based 87 (45.8) 8 (44.5)
Apo C-III, μg/mL 11.27 (4.9) 10.42 (4.7)
Total cholesterol, mmol/L 4.89 (1.2) 4.80 (1.2)
HDL-cholesterol, mmol/L 1.06 (0.4) 1.08 (0.4)
VLDL-cholesterol, mmol/L 0.87 (0.3) 0.64 (0.2)
LDL-cholesterol, mmol/L 2.91 (0.9) 2.88 (0.9)
Triglycerides, mmol/L 2.48 (2.0) 2.40 (2.0)
Glucose, mmol/L 5.39 (0.9) 5.51 (1.0)
CRP, mg/L 4.13 (5.4) 4.91 (6.2)
MCP-1, pg/mL 74.72 (41.8) 81.17 (43.1)
Values are the mean and the standard deviation (SD), unless otherwise
indicated. BMI, body-mass index
Aragonès et al. BMC Medical Genetics 2011, 12:120
http://www.biomedcentral.com/1471-2350/12/120
Page 3 of 8a 12-month follow-up period. As indicated, baseline
values of metabolic parameters were comparable based
on genotype. However, carriers of the A allele had con-
sistently higher serum triglyceride concentration than
non-carriers at three (4.82 ± 2.1 vs. 2.13 ± 1.1 mmol/L;
p = 0.001), six (5.28 ± 2.84 vs. 2.21 ± 1.33 mmol/L; p =
0.003), and twelve (5.76 ± 2.54 vs. 2.43 ± 1.32 mmol/L;
p = 0.019) months, after adjustment of the data for age,
sex, BMI, and HCV co-infection status (Figure 1A).
Results were similar for total cholesterol concentration
(Figure 1B). Carriers of the A allele presented with
higher serum cholesterol values than non-carriers at
three (6.12 ± 1.5 vs. 4.9 ± 1.3 mmol/L; p = 0.01), six
(6.39 ± 1.5 vs. 4.91 ± 1.1 mmol/L; p = 0.006), and twelve
(6.63 ± 1.9 vs. 5.2 ± 1.4 mmol/L; p = 0.034) months.
Also, carriers of the A allele had lower HDL-cholesterol
levels than non-carriers at three (0.94 ± 0.4 vs. 1.17 ±
0.4 mmol/L; p = 0.016), six (1.01 ± 0.3 vs. 1.07 ± 0.4
mmol/L; not significant), and twelve (1.24 ± 0.5 vs. 0.75
± 0.2 mmol/L; p = 0.05) months after adjustment the
data for age, sex, BMI, HCV co-infection status and tri-
glyceride levels (Figure 1C). Both, LDL and VLDL-cho-
lesterol concentrations showed a tendency toward
increase in carriers of the A allele, but these differences
did not reach statistical significance (data not shown).
We separately evaluated a subgroup of 113 patients
who were undergoing treatment with NNRTIs. Baseline
values were also comparable between genotypes, and
there were no differences between genotypes with
respect to serum triglyceride (Figure 2A) or total choles-
terol (Figure 2B) concentrations. However, treatment
with NNRTIs significantly increased HDL-cholesterol
values in patients with the G/G genotype. This differ-
ence with respect to carriers of the A allele was evi-
denced at three (1.04 ± 0.3 vs. 1.37 ± 0.4 mmol/L; p =
0.021), six (1.03 ± 0.3 vs. 1.30 ± 0.4 mmol/L; p = 0.046),
and twelve (1.05 ± 0.3 vs. 1.28 ± 0.4; mmol/L p = 0.05)
months (Figure 2C), after adjustment of the data for
age, sex, BMI, HCV co-infection status and triglyceride
levels.
Discussion
Our study represents the first report of a strong associa-
tion between the rs10892151 A allelic variant and the
expression, particularly during PI-treatment, of a dyslipi-
demic phenotype in HIV-infected patients, which
includes hypertriglyceridemia and depressed HDL-cho-
lesterol levels.
The high prevalence of lipid disorders among treated
HIV-infected patients requires the identification of spe-
cific polymorphisms in candidate genes that might pre-
dispose to these complications. However, the genetic
basis of these metabolic abnormalities remains unclear.
Some studies show that variants of apo A-V and C-III,
interacting with APOE genotypes, are associated with
the severity of antiretroviral treatment-induced dyslipi-
demia. For instance, the most severe dyslipidemic pro-
files after PI therapy were obtained in those patients
carrying the three APOC3 variations (i.e., at nucleotides
-455, -482 and the SstI site) and a non-ε3/ε3 APOE gen-
otype [19-21]. Similarly, Guardiola et al. [22] indicated
that in a cohort of PI treated HIV-infected patients, the
-1131C carriers in APOA5 gene experienced marked
increases in triglyceride levels (up to 80%) during a 3-
year follow-up, while no change was recorded in
patients carrying the normal -1131T allele. More recent
studies [23,24] have associated nucleotide variations in
resistin and b2 adrenegic receptor (ARb2)w i t ht h e
occurrence of lipodystrophy. In addition, tumor necrosis
factor-a (TNFa) [20,25,26] and nuclear transcription-
Table 2 Baseline main metabolic characteristics of HIV-infected patients based on rs10892151 genotype and
treatment strategy
PI-treated patients
(n = 95)
NNRTI-treated patients
(n = 113)
G/G carriers
(n = 87)
A/G carriers
(n =8 )
G/G carriers
(n = 103)
A/G carriers
(n = 10)
BMI, kg/m
2 22.9 (3.1) 23.4 (3.2) 22.6 (2.9) 23.1 (3.1)
ApoC-III, μg/mL 11.12 (5.1) 10.62 (4.6) 11.39 (4.9) 10.26 (4.8)
Total cholesterol, mmol/L 4.91 (1.3) 5.06 (1.3) 4.87 (1.2) 4.60 (1.2)
HDL-cholesterol, mmol/L 1.02 (0.4) 1.06 (0.4) 1.09 (0.4) 1.1 (0.4)
VLDL-cholesterol, mmol/L 0.82 (0.2) 0.54 (0.1) 0.91 (0.4) 0.72 (0.3)
LDL-cholesterol, mmol/L 2.82 (0.8) 2.87 (0.9) 2.88 (0.9) 2.95 (0.9)
Triglycerides, mmol/L 2.65 (2.1) 2.78 (2.2) 2.34 (2.2) 2.10 (2.1)
Glucose, mmol/L 5.68 (1.0) 5.95 (0.9) 5.15 (0.9) 5.16 (0.9)
CRP, mg/L 4.6 (5.4) 5.1 (5.6) 3.73 (5.5) 4.76 (5.7)
MCP-1, pg/mL 73.31 (40.3) 78.76 (43.8) 75.92 (42.1) 83.10 (44.8)
Values are the mean and the standard deviation (SD), unless otherwise indicated. BMI, body-mass index; PI, protease inhibitor; NNRTI, non-nucleoside reverse
transcritase inhibitor
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Carriers of the A allele (closed circles) had significantly increased
serum triglyceride (A) and total cholesterol (B) concentrations
together with depressed levels of HDL-cholesterol (C) when
compared with non-carriers (open circles) at 3, 6, and 12 months
after treatment initiation. * indicates p < 0.05.
Figure 2 Lipid profile changes in patients receiving NNRTI
therapy. No differences were observed between genotypes in
regards to serum triglyceride (A) or total cholesterol (B)
concentrations. However, carriers of the A allele (closed circles) had
significantly decreased HDL-cholesterol values when compared with
non-carriers (open circles) at 3, 6, and 12 months after treatment
initiation (C). * indicates p < 0.05.
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(SREBP1c) [27,28] have also been shown to affect HIV-
induced lipodystrophy, but confirmation is required in
long-term prospective studies.
The intriguing results obtained by Pollin et al.[ 5 ]i n
the polymorphism rs10892151, which is located 800 kb
from the APOC3 gene cluster, prompted us to test the
presence of a genetic association with lipid outcomes in
our patients. In their high-fat feeding intervention study
in 809 Old Order Amish individuals, the authors
observed that rs10892151 A carriers had lower fasting
and post-prandrial serum triglycerides values than non-
carriers, and they found a linkage disequilibrium with
an APOC3 null mutation, which was likely the result of
a founder effect. Conversely, we found that this poly-
morphism in our study has no effect on circulating apo
C-III values in either HIV-infected patients or healthy
subjects, indicating that the linkage disequilibrium
between this two genetic regions could not be universal.
High serum triglyceride concentration and low HDL-
cholesterol values were found in our population, irre-
spective of the treatment they were assigned (although
the effect was notably higher in those patients under PI
treatment), but these lipid disorders were not related to
a differential or abnormal response to circulating apo C-
III levels. In addition, we were not able to identify
further associations between the polymorphism and
other lipid and inflammatory parameters. However,
being a carrier of the rs10892151 A variant was a pri-
mary determinant of the course of lipid alterations. Dur-
ing follow-up, these patients consistently showed higher
serum triglyceride and cholesterol concentrations, as
well as lower HDL-cholesterol levels than those carrying
the G/G genotype. This effect was particularly evident
in those under PI-treatment, although a residual effect
in HDL-cholesterol levels was also evident in those
under NNRTI-treatment indicating that the HIV-infec-
tion itself may have a considerable impact on lipid con-
centrations for patients with the G/A genotype.
However, further studies in larger populations under
other chronic inflammatory stimulus are required to
confirm the direction of rs10892151 polymorphism
effect and to explain the fact that the observed effects in
our study were quite different than expected from HIV
negative individuals as previously reported [5].
Although the design of our study cannot address the
mechanism by which antiretroviral treatment and HIV-
infection interact with the polymorphism, it could be
argued that antiretroviral treatment may interfere in the
functioning of lipolytic enzymes, [29,30] which are regu-
lated by serum apo C-III concentrations, decreasing the
catabolism of triglyceride-rich proteins in carriers of the
rs10892151 A allele. However it does not explain why
antiretroviral treatment and rs10892151 genetic
variation have a limited impact on apo C-III levels,
probably masked by the concomitant metabolic effects
described during HIV infection. Despite the fact that
our HIV-infected patients showed higher levels of apo
C-III than healthy controls, the described effect was
influenced by rs10892151 genotype rather than by
serum apo C-III concentration. It is also noteworthy
that there is a highly significant gene-nutrient interac-
tion and that dietary manipulation may modulate the
effect of polymorphisms on lipid profile [31].
Another possibility is that antiretroviral treatment may
not affect just lipoprotein metabolism, but may exacer-
bate the chronic inflammatory state by the expression of
pro-inflammatory molecules such as TNFa or MCP-1,
which have a major role in lipid metabolism and, conse-
quently, in cardiovascular disease [14,32-34]. However,
this hypothesis is not supported by our findings that the
plasma MCP-1 and CRP concentrations were essentially
t h es a m ei nb o t hg r o u p so fH I V - i n f e c t e dp a t i e n t sa s
well as in both genotypes.
The peculiar distribution of alleles seriously limits the
reach of our conclusions but the differential response
and pharmacogenetic implications among patients with
different treatment strongly reinforces the need for repli-
cation. According to our data, this should be done in a
sample with same ethnic origin and a sample size only
achievable in multicenter-multicohort studies. The
impact of population stratification in this study is unli-
kely because in our population sample this has been
already assessed empirically by analyzing more than 25
unlinked single-nucleotide polymorphisms (SNPs) in sev-
eral association studies spanning a range of disease states
[35-39] and cases selected under the same circumstances.
We also acknowledge that studies assessing only one
polymorphism are less robust than those assessing sev-
eral polymorphisms associated with a plausible role in
the pathogenesis of dyslipidemia. Further studies are
needed to assess the possibly coordinated association
with other well-documented polymorphisms, particularly
those involved in metabolism and in molecular targets
of antiretroviral drugs in order to uncover a host-related
predisposition towards developing metabolic complica-
tions. If successful this may aid for specific, individual
design of antiretroviral regimens to diminish the rapid
emergence of side effects and the consequent deleterious
significance.
Conclusions
These results suggest that the rs10892151 A allelic var-
iant could be associated in HIV-infected patients with
less favorable lipid profile, particularly those treated
with PIs. The exact mechanism for this putative effect is
unknown but, considering the therapeutic implications,
clarification deserves further research.
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